1 / 16

Novartis Biomedical Research sites

Approach to Rare Diseases Research and Orphan Products Development John J. Orloff , MD Chief Medical Officer Novartis Pharma AG US-Russia Scientific Forum November 16 th , 2011. Novartis Biomedical Research sites. Cambridge, MA: Cardiovascular&Metabolism Infectious Diseases

ellis
Download Presentation

Novartis Biomedical Research sites

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Approach to Rare Diseases Research and Orphan Products DevelopmentJohn J. Orloff, MDChief Medical OfficerNovartis Pharma AGUS-Russia Scientific ForumNovember 16th, 2011

  2. Novartis Biomedical Research sites • Cambridge, MA: • Cardiovascular&Metabolism • Infectious Diseases • Misculoskeletrical Diseases • Oncology • Ophtalmology • Vaccines (NV&D) Siena, Italy: NVGH, Novartis Institute for Global Health ~ 6000 scientists ~ USD 2 bn/year • UK: • Respiratory • Gastrointestinal • Siena, Italy: • Vaccines Singapore: NITD, Novartis Institute for Tropical Diseases • Switzerland: • Autoimmunity, Transplantation and Inflammation • Oncology • Neuroscience • Musculoskeletal Diseases • Gastrointestinal • Emeryville, CA: • Oncology • Shanghai, China: • Oncology La Jolla, CA. GNF, Genomic Institute of the Novartis Research Foundation Indonesia: NEHCRI, the NITD – Eijkman Institute– Hasanuddin University Clinical Research Initiative Basel, Switzerland: FMI, Friedrich Miescher Institute Novartis Institutes for Biomedical Research (NIBR) Novartis Institutes for Developing World Medical Research (part of NIBR) Novartis Vaccines and Diagnostics (NV&D)

  3. R&D innovation guided by science and medical need Understanding molecular biology Proof of Concept (PoC) clinical trials Parallel indication expansion studies Illustrative: PoC indication Expansion 1 Expansion 2 Protein networks, molecular pathways, are the functional units of the cell Expansion 3 1X Expansion n 1.5X

  4. CAPS: Broad spectrum of diseases resulting from over-expression of Interleukin-1Cryopyrin Associated Periodic Syndrome (CAPS) Familial cold autoinflammatory syndrome (FCAS) • Autosomal dominant • Rash, Arthralgia, Conjunctivitis Mild Muckle–Wells syndrome (MWS) • Autosomal dominant • Rash, fever, fatigue, sensorineural deafness • AA amyloidosis (in 25% of patients) leading to renal failure Moderate NOMID/CINCA • Sporadic • Progressive chronic meningitis, deafness • Visual and intellectual damage • Destructive arthritis Severe

  5. Ilaris® (ACZ885): Anti-IL-1β antibodyNIBR Strategy: Proof of Concept in Homogeneous Population followed by Mechanistic Expansion CAPS1<0.020 Million Gout 20 Million Atherosclerosis 130 Million Normal vessel Inflammation Monosodium urate crystals Cholesterol crystals 1- Cryopyrin-associated periodic syndromeSource for patient numbers: global prevalence estimate from Patient Base Latz, et al., Nature, Vol 464|29 April 2010

  6. Why understanding one disease can be importantIL-1β Pathway - abnormal signal transduction leading to disease Multiple diseases One pathway One node CAPS 1 NALP3 (Cryopyrin) Inflammasome SJIA 2 Activation of Caspase-1 Chronic Gout Inflammation(IL-1β Pathway) Caspase-1 IL-1βPrecursor CV Risk Reduction Caspase-1 Osteoarthritis Activated IL-1β COPD 3 1Cryopyrin-associated periodic syndrome 2 Systemic juvenile idiopathic Arthritis 3 Chronic obstructive pulmonary disease

  7. PsoriasisCD3+IL-17+ cells Multiple sclerosis Rheumatoid arthritisCD3_CD4+IL-17+ plasmacytoid-like cells CD3 IHC Aperio color deconvolution method A Haider et al, NIBR Page et al., Am J Pathol 2004;164:409 IL17 IHC Crohn’s disease Langerhans cell histiocytosisskin lesion CD3+ T cells CD68+ Cells Tzartos et al., Am J Pathol 2008;172:146 Fujino et al., Gut 2003; 52:65 Coury et al., Nature Med 2008;14:81 IL-17 Pathway in the Clinic:Psoriasis and related immune mediated diseases

  8. AIN457: mAB against IL-17Parallel indication expansion Top 7 Markets3 BechetsUveitis 3,000-6,000 in PhIII Non infectious posteriorsegment uveitis 50,000 – 75,000 in PhIII RA1 in PhII 5 million Psoriasis (Moderate to severe) in PhII 1.2 million AS2 in PoC 1.2 million Psoriatic Arthritis in PoC 800,000 MS in PoC 600,000 Crohn’s Disease in PoC 570,000 1 Rheumatoid arthitis 2Ankylosingspondylitis 3 Not all potential patients would be eligible for treatment with AIN457, if approved

  9. Tuberous Sclerosis : Rare Autosomal Dominant Genetic Disease • Estimated to be 1 in 6,000 live births • 1-2 million worldwide (50,000 US) • All sexes, races, and ethnicities • Benign tumors (hamartomas) interfering with organ function • Common sites are skin, kidney, brain, lung, eyes, and heart • Skin lesions including facial angiofibromas in >90% of patients • Neurologic manifestations are predominant clinical feature • Epilepsy in 70-80% due to cortical tubers • SEGAs (subependymal giant cell astrocytoma) in 5-20%; associated with hydrocephalus and increased intracranial pressure Figure from Krueger and Franz. Pediatr Drugs. 2008;10:299-313, with permission.

  10. Growth of Afinitor® (mTOR Inhibitor) driven by continued indication expansion Approved1 Approved Metastatic breast cancer3 160k+ Neuroendocrine tumors (NET) 60k+ TSC SEGA2 Unknown Renal cell carcinoma 590k Number of patients 1 By FDA; Submitted in EU 2 Tuberous Sclerosis Complex Subependymal giant cell astrocytomas 3 Phase III studies in ER+ breast cancer and HER2+ breast cancerSource: (RCC) Globocan worldwide prevalence; (NET) Yao JC et al, JCO 2008; (Breast Cancer) PLAN A, global oncology epidemiology database (figure shown represents metastatic breast cancer in US, EU5, and Japan only)

  11. One pathway/NME - multiple target indications Kidney C SJIA OA Gastric C mTOR Tub Scl IL-1β Liver C COPD Gout Breast C NET Tx CAPS Lymph. CV Risk Psor. RA Ank. Sp. IL-17 Cr. dis Ps. Arth. MS

  12. Orphan Drugs: Recent Trends in approvals • During the 2000s, orphan products comprised 22% of all NMEs and 31% of all SBs receiving US marketing approval • The number of orphan product designations increased from 208 in 2000-02 to 425 in 2006-08 • Novartis has 39 orphan designations and 18 orphan approvals to date

  13. Orphan Drug Approvals 2009 BioMarket Trends: Jun 15 2010 (Vol. 30, No. 12)

  14. Orphan Drug Legislation • The US Orphan Drug Act has been a success in encouraging many new drug approvals for rare diseases • More than 2100 orphan designations • Designations more than doubled during past decade • Over 350 approvals for orphan products • Similar orphan drug legislation (ODL) in other countries (EU, Japan, Australia) • But, only ~200 of > 6000 rare diseases have an approved Rx • Additional “Push” and “pull” incentives could foster greater investment in rare (and neglected) diseases

  15. Mechanisms to spur innovation for Orphan Diseases • “Push” mechanisms • Increase grant and research funding • Stronger partnership among key stakeholders (HA, industry, academia, advocacy groups), including “de-risking” programs • Increase and expand R&D tax credit to neglected diseases • “Pull” mechanisms • Extend market exclusivity (10 years) and include neglected diseases (clearly defined) • Favorable reimbursement approach – automatic • For NMEs, consider patent extension on the molecule (e.g. 6 mo similar to pediatrics) • Advance market commitments (AMCs) – subsidize purchase of product after development • Priority review voucher system (PRV) – expand and improve

  16. Opportunities and Incentives for Orphan Drugs and Neglected Diseases: Regulatory Flexibility • Apply existing regulations with greater flexibility to foster development (accelerated approval program) • Reduced requirements for clinical and preclinical program, including smaller trials and safety databases, historical controls, retrospective analyses , observational data, etc. – establish global standards (ICH) • Consider acceptance of biomarkers (e.g. PD endpoints) as surrogates for approval (reduced burden for qualification) • Conditional approval for rare & neglected diseases • Global harmonization of regulatory requirements • Partner with WHO and other health authorities – leverage expertise

More Related